Canada NewsWire
QUINCY, FL, Sept. 24, 2018
QUINCY, FL, Sept. 24, 2018 /CNW/ - Trulieve Cannabis Corp.
(CSE: TRUL) ("Trulieve" or the "Company") today announces its financial results for the three and six-month periods ended
June 30, 2018. The Company's second quarter 2018 financial statements have been filed as part of
its listing statement with the Canadian Securities Exchange ("CSE"). This news release is not in any way a substitute for reading
those financial statements, including the notes to the financial statements.
Unless otherwise stated, all currency is expressed in U.S. dollars.
Q2 2018 Highlights
- 16 dispensaries in operation
- 83,000 active unique patients
- Revenue grew from $15.2 million in Q1 2018 to $23.3 million in
Q2 2018.
- EBITDA1 increased from $11.2 million in Q1 2018 to $14.3
million in Q2 2018
"The second quarter of 2018 demonstrated our ability to scale our business profitably with growth in dispensaries and patients
served driving growth in revenue and EBITDA1," said Kim Rivers, CEO of Trulieve. "This
momentum is continuing in the current quarter and we expect strong results throughout 2018."
Results of Operations
|
(millions of U.S. dollars)
|
2017
|
2018 Q1
|
% change
|
2018 Q2
|
|
Total Revenue
|
19.8
|
15.2
|
53.3
|
23.3
|
|
Gross Margin2
|
8.7
|
10.7
|
61.7
|
17.3
|
|
Gross Margin %
|
43.9
|
69.3
|
6.9
|
74.1
|
|
Operating Expenses
|
8.3
|
4.6
|
30.4
|
6.0
|
|
Operating Expenses %
|
42.0
|
30.1
|
(14.3)
|
25.8
|
|
EBITDA1
|
10.1
|
11.2
|
27.7
|
14.3
|
|
1.
|
EBITDA is a non-IFRS financial measure. While Trulieve believes that this
measure is useful for the evaluation and assessment of its performance, it does not have any standard meaning prescribed
by IFRS, is unlikely to be comparable to similar measures presented by other issuers, and should not be considered as an
alternative to comparable measures determined in accordance with IFRS.
|
|
2.
|
Gross Margin does not include net-effect of change in fair value of
biological assets i.e. gain on biological assets.
|
About Trulieve
Trulieve is a vertically integrated "seed to sale" company and is the first and largest fully licensed medical
cannabis company in the State of Florida. Trulieve cultivates and produces all of its products
in-house and distributes those products to Trulieve branded stores (dispensaries) throughout the State
of Florida, as well as directly to patients via home delivery. This press release does not constitute an offer to sell or
a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States
Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered or sold within the United States
(as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state
securities laws or pursuant to an exemption from such registration requirements.
SOURCE Trulieve Cannabis Corp.
View original content: http://www.newswire.ca/en/releases/archive/September2018/24/c5639.html